Gynecologic Oncology | Specialty

The OncLive Gynecologic Oncology condition center page is a comprehensive resource for clinical news and expert insights on various types of gynecologic cancers, including ovarian cancer, endometrial cancer, and uterine cancer, among others. This section features news articles, interviews with gynecologic oncologists in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in gynecologic cancers.

Gynecologic Cancer Research Thrives at The Ohio State University

November 21st 2019

Experts from The Ohio State University and Allegheny Health Network discuss the exciting research being conducted at their institutions.

Individualized Approach Imperative in Frontline Ovarian Cancer

November 20th 2019

Ritu Salani, MD, discusses the evolution of up-front chemotherapy, as well as the roles of primary debulking surgery and neoadjuvant chemotherapy in ovarian cancer.

O'Malley Highlights Pivotal Trials in Ovarian Cancer

November 19th 2019

David O’Malley, MD, discusses clinical trials in ovarian cancer and others under investigation.

Genetic Testing Is Suggested First Step Upon Ovarian Cancer Diagnosis

November 18th 2019

Leigha Senter, MS, LGC, discusses the current state of genetic testing for patients with ovarian cancer.

Dr. Leath on Agents Under Investigation in Cervical Cancer

November 15th 2019

Charles A. Leath III, MD, gynecologic oncologist at the University of Alabama at Birmingham, discusses agents under investigation in cervical cancer.

Dr. Coleman on Ongoing Research in Cervical Cancer

November 14th 2019

Robert L. Coleman, MD, FACOG, FACS, discusses ongoing research efforts in cervical cancer.

Dr. Backes on Safety Profile of Lenvatinib and Weekly Paclitaxel in Endometrial Cancer

November 12th 2019

Floor J. Backes, MD, discusses the safety profile from a phase I study looking at lenvatinib and weekly paclitaxel in women with recurrent endometrial cancer.

Dr. Yadav on Differences in Type 1 and Type 2 Uterine Cancer

November 12th 2019

Ghanshyam Yadav, MD, discusses the differences between type 1 and type 2 uterine cancer.

Dr. Coleman on Investigational Treatment Strategies in Cervical Cancer

November 8th 2019

Robert L. Coleman, MD, FACOG, FACS, professor and Ann Rife Cox Chair in Gynecology, Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses investigational treatment strategies in cervical cancer.

Efforts Continue to Perfect PARPi Use in Ovarian Cancer

November 8th 2019

As PARP inhibitors have now moved into the frontline maintenance setting in ovarian cancer, researchers are now seeking to even further capitalize on use of these agents, including indications in treatment-naïve patients.

Dr. Leath on the Results of the GOG 240 Trial in Advanced Cervical Cancer

November 7th 2019

Charles A. Leath III MD, gynecologic oncologist at the University of Alabama at Birmingham, discusses results of the phase III GOG 240 trial in advanced cervical cancer.

Dr. Backes on Next Steps for Lenvatinib and Weekly Paclitaxel in Endometrial Cancer

November 5th 2019

Floor J. Backes, MD, discusses the next steps regarding a phase I trial investigating lenvatinib and weekly paclitaxel in women with recurrent endometrial cancer.

Dr. Ferguson on the Impact of the LACC Trial Data on Cervical Cancer Surgery

November 1st 2019

Sarah Ferguson, MD, discusses how the results from the LACC trial, which compared minimally invasive surgery with open surgery in patients with IA1, IA2, or IB1 cervical cancer, are impacting surgery in the cervical cancer field.

Outlining Progress Made in Ovarian Cancer in Pittsburgh

October 24th 2019

We traveled to Pittsburgh, Pennsylvania, for a State of the Science Summit™ on Ovarian Cancer, which featured insights from the University of Pittsburgh Medical Center faculty.

Dr. Hong on Moving Tisotumab Vedotin to Frontline Therapy for Cervical Cancer

October 18th 2019

David S. Hong, MD, discusses the potential of moving tisotumab vedotin (HuMax-TF-ADC) to the frontline setting in cervical cancer.

Dr. Backes on Rationale for Lenvatinib and Weekly Paclitaxel in Endometrial Cancer

October 15th 2019

Floor J. Backes, MD, discusses the rationale and results from a phase I study exploring lenvatinib and weekly paclitaxel in women with recurrent endometrial cancer.

NICE Approves Maintenance Rucaparib for Relapsed Ovarian Cancer

October 11th 2019

The UK’s National Institute for Health and Care Excellence has approved rucaparib for the maintenance treatment of patients with relapsed ovarian, fallopian tube, or peritoneal cancer that has responded to platinum-based chemotherapy.

Dr. Coleman on the Use of Immunotherapy in Cervical Cancer

October 10th 2019

Robert L. Coleman, MD, FACOG, FACS, professor in the Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, discusses the use of immunotherapy in patients with cervical cancer.

Dr. Oaknin on the Rationale for the GARNET Trial in Endometrial Cancer

October 9th 2019

Ana Oaknin, MD, principal investigator, Gynecological Malignancies Group, Vall d’Hebron Institute of Oncology, head of Gynecologic Tumors Unit, senior medical oncologist and attending physician, Medical Oncology Department, Vall d’Hebron University Hospital, discusses the rationale for the phase I/II GARNET trial in endometrial cancer.

PARP Inhibitors Continue to Flourish in Advanced Ovarian Cancer

October 7th 2019

Reagan M. Street, MD, MMS, discusses the shift toward targeted treatment in advanced ovarian cancer partly brought on by PARP inhibitors and the importance of hierarchical genomic testing.